These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
189 related articles for article (PubMed ID: 33911188)
1. Reversal of hypertriglyceridemia in diabetic BTBR ob/ob mice does not prevent nephropathy. Attie AD; Schueler KM; Keller MP; Mitok KA; Simonett SP; Hudkins KL; Mehrotra K; Graham MJ; Lee RG; Alpers CE Lab Invest; 2021 Jul; 101(7):935-941. PubMed ID: 33911188 [TBL] [Abstract][Full Text] [Related]
2. Reversibility of structural and functional damage in a model of advanced diabetic nephropathy. Pichaiwong W; Hudkins KL; Wietecha T; Nguyen TQ; Tachaudomdach C; Li W; Askari B; Kobayashi T; O'Brien KD; Pippin JW; Shankland SJ; Alpers CE J Am Soc Nephrol; 2013 Jun; 24(7):1088-102. PubMed ID: 23641056 [TBL] [Abstract][Full Text] [Related]
3. Beneficial effect on podocyte number in experimental diabetic nephropathy resulting from combined atrasentan and RAAS inhibition therapy. Hudkins KL; Wietecha TA; Steegh F; Alpers CE Am J Physiol Renal Physiol; 2020 May; 318(5):F1295-F1305. PubMed ID: 32249614 [TBL] [Abstract][Full Text] [Related]
4. Effects of CP-900691, a novel peroxisome proliferator-activated receptor α, agonist on diabetic nephropathy in the BTBR ob/ob mouse. Askari B; Wietecha T; Hudkins KL; Fox EJ; O'Brien KD; Kim J; Nguyen TQ; Alpers CE Lab Invest; 2014 Aug; 94(8):851-62. PubMed ID: 24955894 [TBL] [Abstract][Full Text] [Related]
5. Regression of diabetic nephropathy by treatment with empagliflozin in BTBR ob/ob mice. Hudkins KL; Li X; Holland AL; Swaminathan S; Alpers CE Nephrol Dial Transplant; 2022 Apr; 37(5):847-859. PubMed ID: 34865099 [TBL] [Abstract][Full Text] [Related]
6. Grem2 mediates podocyte apoptosis in high glucose milieu. Wen H; Kumar V; Mishra A; Song S; Aslam R; Hussain A; Wang H; Zhou X; He X; Wu G; Luo H; Lan X; Malhotra A; Singhal PC Biochimie; 2019 May; 160():113-121. PubMed ID: 30831151 [TBL] [Abstract][Full Text] [Related]
7. Pharmacological PAR-1 inhibition reduces blood glucose levels but does not improve kidney function in experimental type 2 diabetic nephropathy. Waasdorp M; Florquin S; Duitman J; Spek CA FASEB J; 2019 Oct; 33(10):10966-10972. PubMed ID: 31287960 [TBL] [Abstract][Full Text] [Related]
8. The SGLT2 inhibitor empagliflozin ameliorates early features of diabetic nephropathy in BTBR ob/ob type 2 diabetic mice with and without hypertension. Gembardt F; Bartaun C; Jarzebska N; Mayoux E; Todorov VT; Hohenstein B; Hugo C Am J Physiol Renal Physiol; 2014 Aug; 307(3):F317-25. PubMed ID: 24944269 [TBL] [Abstract][Full Text] [Related]
13. Emerging role of podocyte autophagy in the progression of diabetic nephropathy. Yasuda-Yamahara M; Kume S; Tagawa A; Maegawa H; Uzu T Autophagy; 2015; 11(12):2385-6. PubMed ID: 26565953 [TBL] [Abstract][Full Text] [Related]
14. Oral anserine supplementation does not attenuate type-2 diabetes or diabetic nephropathy in BTBR ob/ob mice. Everaert I; Van der Stede T; Stautemas J; Hanssens M; van Aanhold C; Baelde H; Vanhaecke L; Derave W Amino Acids; 2021 Aug; 53(8):1269-1277. PubMed ID: 34264387 [TBL] [Abstract][Full Text] [Related]
15. APOC-III Antisense Oligonucleotides: A New Option for the Treatment of Hypertriglyceridemia. Schmitz J; Gouni-Berthold I Curr Med Chem; 2018; 25(13):1567-1576. PubMed ID: 28595549 [TBL] [Abstract][Full Text] [Related]
16. The compositional abnormalities of lipoproteins in diabetic renal failure. Attman PO; Knight-Gibson C; Tavella M; Samuelsson O; Alaupovic P Nephrol Dial Transplant; 1998 Nov; 13(11):2833-41. PubMed ID: 9829487 [TBL] [Abstract][Full Text] [Related]
17. Effect of hepatic insulin expression on lipid metabolism in diabetic mice. Qu S; Zhang T; Dong HH J Diabetes; 2016 May; 8(3):314-23. PubMed ID: 25851734 [TBL] [Abstract][Full Text] [Related]
18. Dysregulation of low-density lipoprotein receptor contributes to podocyte injuries in diabetic nephropathy. Zhang Y; Ma KL; Liu J; Wu Y; Hu ZB; Liu L; Liu BC Am J Physiol Endocrinol Metab; 2015 Jun; 308(12):E1140-8. PubMed ID: 25921580 [TBL] [Abstract][Full Text] [Related]
19. Absence of miR-146a in Podocytes Increases Risk of Diabetic Glomerulopathy via Up-regulation of ErbB4 and Notch-1. Lee HW; Khan SQ; Khaliqdina S; Altintas MM; Grahammer F; Zhao JL; Koh KH; Tardi NJ; Faridi MH; Geraghty T; Cimbaluk DJ; Susztak K; Moita LF; Baltimore D; Tharaux PL; Huber TB; Kretzler M; Bitzer M; Reiser J; Gupta V J Biol Chem; 2017 Jan; 292(2):732-747. PubMed ID: 27913625 [TBL] [Abstract][Full Text] [Related]